肺癌相关静脉血栓栓塞症的预测与风险评估进展
Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism.
作者信息
Di Wenjuan, Xu Haotian, Xue Ting, Ling Chunhua
机构信息
Department of Respiratory and Critical Care Medicine, The First Hospital Affiliated of Soochow University, Suzhou City, Jiangsu Province, People's Republic of China.
出版信息
Cancer Manag Res. 2021 Nov 4;13:8317-8327. doi: 10.2147/CMAR.S328918. eCollection 2021.
Abstract
According to the most recent data from the National Cancer Center, venous thromboembolism (VTE) has unsurprisingly become one of the most common complications in lung cancer. VTE not only interferes with the equilibrium of the clotting system but it also affects tumor progression and prognosis. For the identification of high-risk patients, many clinical risk assessment models have been developed and validated based on the risk factors found in previous studies. In this review, we will summarize advances in prediction and risk assessment of VTE, with a focus on early diagnosis and therapy, reduction of mortality, and the burden of medical costs in lung cancer patients.
摘要
根据国家癌症中心的最新数据，静脉血栓栓塞（VTE）不出所料地成为肺癌最常见的并发症之一。VTE不仅会干扰凝血系统的平衡，还会影响肿瘤进展和预后。为了识别高危患者，基于以往研究中发现的风险因素，已经开发并验证了许多临床风险评估模型。在这篇综述中，我们将总结VTE预测和风险评估方面的进展，重点关注肺癌患者的早期诊断和治疗、降低死亡率以及医疗成本负担。
相似文献
1
Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism.肺癌相关静脉血栓栓塞症的预测与风险评估进展
Cancer Manag Res. 2021 Nov 4;13:8317-8327. doi: 10.2147/CMAR.S328918. eCollection 2021.
2
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).肺癌静脉血栓栓塞症和早期死亡率的预测因素：一项全球前瞻性研究（CANTARISK）的结果。
Oncologist. 2018 Feb;23(2):247-255. doi: 10.1634/theoncologist.2017-0205. Epub 2017 Sep 26.
3
[Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].基于COMPASS-CAT风险评估模型的非小细胞肺癌患者静脉血栓栓塞症风险预测
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):340-345. doi: 10.3760/cma.j.cn112152-20191101-00707.
4
Venous thromboembolism in cancer patients.癌症患者的静脉血栓栓塞
Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156.
5
A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer.系统评价肺癌患者静脉血栓栓塞症的风险预测模型。
Thorac Cancer. 2024 Feb;15(4):277-285. doi: 10.1111/1759-7714.15219. Epub 2024 Jan 17.
6
Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer.门诊肺癌患者静脉血栓栓塞的危险因素及预测模型
Healthcare (Basel). 2021 Jun 21;9(6):778. doi: 10.3390/healthcare9060778.
7
Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model.肺癌合并静脉血栓栓塞症患者的早期识别：风险预测模型的建立与验证
Thromb J. 2023 Sep 14;21(1):95. doi: 10.1186/s12959-023-00544-w.
8
External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.实体瘤癌症门诊患者静脉血栓栓塞风险评分的外部验证：COMPASS-CAT 静脉血栓栓塞风险评估模型。
Oncologist. 2020 Jul;25(7):e1083-e1090. doi: 10.1634/theoncologist.2019-0482. Epub 2020 Feb 4.
9
Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol.预测肺癌门诊患者静脉血栓栓塞症的模型：系统评价方案。
BMJ Open. 2021 Dec 1;11(12):e055322. doi: 10.1136/bmjopen-2021-055322.
10
[Risk factors of lung cancer complicated with symptomatic venous thromboembolism].[肺癌合并有症状静脉血栓栓塞症的危险因素]
Zhonghua Jie He He Hu Xi Za Zhi. 2016 Jun;39(6):454-8. doi: 10.3760/cma.j.issn.1001-0939.2016.06.010.
引用本文的文献
1
Machine learning-based preoperative prediction of perioperative venous thromboembolism in Chinese lung cancer patients: a retrospective cohort study.基于机器学习的中国肺癌患者围手术期静脉血栓栓塞症的术前预测：一项回顾性队列研究
Front Oncol. 2025 Jun 25;15:1588817. doi: 10.3389/fonc.2025.1588817. eCollection 2025.
2
Didang decoction attenuates cancer-associated thrombosis by inhibiting PAD4-dependent NET formation in lung cancer.抵当汤通过抑制肺癌中依赖于瓜氨酸化酶4的中性粒细胞胞外陷阱形成来减轻癌症相关血栓形成。
Pulm Circ. 2024 Oct 9;14(4):e12454. doi: 10.1002/pul2.12454. eCollection 2024 Oct.
3
Venous Thromboembolism in Burn Patients: A 5-Year Retrospective Study.烧伤患者静脉血栓栓塞症：一项 5 年回顾性研究。
Medicina (Kaunas). 2024 Feb 2;60(2):258. doi: 10.3390/medicina60020258.
4
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.肺癌相关血栓形成（LCART）：聚焦免疫检查点阻断疗法
Cancers (Basel). 2024 Jan 20;16(2):450. doi: 10.3390/cancers16020450.
5
Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis.肺癌相关静脉血栓栓塞危险因素的分层及确定预防性干预的临界点：一项Meta分析的系统评价
Clin Med Insights Oncol. 2023 Jun 28;17:11795549231175221. doi: 10.1177/11795549231175221. eCollection 2023.
6
Could PD-L1 positivity be associated with venous thrombosis in patients with non-small cell lung cancer?PD-L1 阳性是否与非小细胞肺癌患者的静脉血栓形成有关？
J Thromb Thrombolysis. 2023 Feb;55(2):382-391. doi: 10.1007/s11239-022-02753-y. Epub 2022 Dec 24.
7
Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.基于列线图的肺癌住院患者静脉血栓栓塞症新型风险评估模型的推导、验证与评估：一项回顾性病例对照研究
Front Oncol. 2022 Oct 10;12:988287. doi: 10.3389/fonc.2022.988287. eCollection 2022.
8
Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.制定并验证了一个列线图模型，用于评估 IA 期非小细胞肺癌患者术后静脉血栓栓塞风险。
Cancer Med. 2023 Jan;12(2):1217-1227. doi: 10.1002/cam4.4982. Epub 2022 Jun 27.
本文引用的文献
1
Cancer incidence and mortality in China, 2015.2015年中国的癌症发病率和死亡率
J Natl Cancer Cent. 2020 Dec 17;1(1):2-11. doi: 10.1016/j.jncc.2020.12.001. eCollection 2021 Mar.
2
Venous Thromboembolism in Patents With Lung Cancer.肺癌患者的静脉血栓栓塞症。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620977910. doi: 10.1177/1076029620977910.
3
Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.癌症相关血栓形成的治疗和预防临床实践指南。
Thromb Res. 2020 Jul;191 Suppl 1:S79-S84. doi: 10.1016/S0049-3848(20)30402-3.
4
Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients.肿瘤基因组突变对癌症患者血栓形成风险的影响
Cancers (Basel). 2020 Jul 19;12(7):1958. doi: 10.3390/cancers12071958.
5
Risk Factors and Clinical Significance of D-Dimer in the Development of Postoperative Venous Thrombosis in Patients with Lung Tumor.肺肿瘤患者术后静脉血栓形成中D-二聚体的危险因素及临床意义
Cancer Manag Res. 2020 Jun 30;12:5169-5179. doi: 10.2147/CMAR.S256484. eCollection 2020.
6
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm.癌症患者中的直接口服抗凝剂。是时候改变范式了。
Cancers (Basel). 2020 May 2;12(5):1144. doi: 10.3390/cancers12051144.
7
From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.从经典实验室参数到新型生物标志物用于静脉血栓栓塞症的诊断。
Int J Mol Sci. 2020 Mar 11;21(6):1920. doi: 10.3390/ijms21061920.
8
Potential Mechanisms of Cancer-Related Hypercoagulability.癌症相关高凝状态的潜在机制。
Cancers (Basel). 2020 Feb 29;12(3):566. doi: 10.3390/cancers12030566.
9
ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis.ONKOTEV 评分作为预测胰腺癌血栓栓塞事件的工具：一项回顾性分析。
Oncologist. 2020 Feb;25(2):e284-e290. doi: 10.1634/theoncologist.2019-0510. Epub 2019 Oct 22.
10
Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management?直接口服抗凝剂在肺癌相关静脉血栓栓塞症管理中作为低分子肝素的经济吸引力替代物？
J Thromb Thrombolysis. 2020 Oct;50(3):642-651. doi: 10.1007/s11239-020-02047-1.
Zotero 插件